AMP Health Review
AMP Health is no longer available as we reviewed it, so this page is kept for reference.
AMP Health: Site is down for maintenance and not taking orders. We're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.
See our top-rated GLP-1 providers →AMP Health was a telehealth service that sold compounded semaglutide (injectable and oral) and tirzepatide with a monthly subscription fee on top, and it appears to be a rebrand of the earlier SlimMD service. Its website has shown only a maintenance page since at least June 2026, with no store, prices or sign-up, so it is not taking orders.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Vetted alternatives to AMP Health
Ro
Best for: FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Editorial score · methodology
Collective
Best for: the lowest flat medication price if you can absorb an annual membership fee
Editorial score · methodology
CoreAge Rx
Best for: lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Editorial score · methodology
AMP Health at a glance
- Type
- GLP-1 telehealth provider
- FDA status
- 1 FDA warning letter on record; see below
How we scored AMP Health
Each dimension is scored algorithmically from AMP Health'spublished pricing, drugs offered, verification status, and disclosed inclusions, using the same six-dimension framework we apply to every provider.
Value25%
6.8/10AMP Health no longer sells GLP-1 treatment, so no current price applies.
Effectiveness25%
6.2/10AMP Health no longer offers GLP-1 treatment, so there is no current medication lineup to assess.
User Experience15%
7.6/10Online intake and platform experience; 2 platform features disclosed.
Trust & Safety15%
5.7/10Core details confirmed by our editors; an FDA warning letter is on file (see the regulatory notice on this page).
Accessibility10%
6.8/10AMP Health no longer offers GLP-1 treatment, so state availability no longer applies.
Support10%
6.6/10AMP Health no longer offers GLP-1 treatment, so there is no current patient support to assess.
Each checked against the provider’s own site.
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
How we verified this AMP Health review
Last checked August 2026- Checked the FDA warning-letter database for enforcement actions
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records. See the sources below. Editorial confidence in this data: medium.
What we checked
- FDA warning-letter register
- An active letter is on file for this provider; see below
What we like
- Review page kept live so readers searching for it get a straight answer
Watch-outs
- The website shows only a maintenance page, so there is no way to sign up, see prices or reorder
- The maintenance page still advertises a free first month, with no working way to claim it
- It never showed LegitScript or PCAB accreditation or a physical address
AMP Health's website shows only a maintenance page, and it is not taking orders
If you came here looking for AMP Health's compounded semaglutide or tirzepatide, there is nothing to order. When we checked on October 30, 2026, its website still showed only a maintenance page, as it has since at least June 2026. There is no store, no price list and no sign-up, even though the page still advertises a free first month.
When it was selling, AMP Health offered compounded semaglutide as an injection and an oral form, plus compounded tirzepatide, with a monthly subscription fee charged on top of the medication. The site's code still referenced an older SlimMD logo, which suggests it was a rebrand of an earlier service. It never showed LegitScript or PCAB accreditation or a physical address. We treat it as closed until it comes back with a working store.
What to do if you were a patient
Talk with a prescriber before your current supply runs out. A GLP-1 dose should be continued or adjusted on clinical advice, not interrupted because a provider stopped selling, and restarting at a high dose after a gap can be unsafe. If your medication label names a pharmacy, keep that information handy, because the dispensing pharmacy is a separate business from the platform that arranged your visits.
If you were taking the oral form, bring your current dose and how long you have been on it to your first visit with a new provider, since oral and injected semaglutide are dosed very differently.
Where to look instead
The alternatives listed on this page are all currently operating and carry current prices. You can also start from our semaglutide provider rankings and compare what each provider includes as well as what it charges, using the factors in our scoring methodology.
Bottom line
AMP Health is not taking orders, and its website has shown only a maintenance page for months. We keep this page up so people searching for it get a clear answer rather than a dead link. It is excluded from our rankings and carries no outbound link.
The Bottom Line
AMP Health is no longer available as we reviewed it, so this page is kept for reference.
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
AMP Health received an FDA warning letter dated February 20, 2026
The letter concerns false and misleading claims and misbranded drugs. FDA warning letters are public regulatory communications and do not, on their own, constitute a finding of illegal activity. Companies often respond with corrective action.
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this AMP Health review:
Sources & methodology (as of November 2026)
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 4.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.